Engineering interferons for cancer immunotherapy - 20/09/24
Abstract |
Interferons are a family of cytokines that are famously known for their involvement in innate and adaptive immunity. Type I interferons (IFNs) exert pleiotropic effects on various immune cells and contribute to tumor-intrinsic and extrinsic mechanisms. Their pleiotropic effects and ubiquitous expression on nucleated cells have made them attractive candidates for cytokine engineering to deliver to largely immunosuppressive tumors. Type III interferons were believed to play overlapping roles with type I IFNs because they share a similar signaling pathway and induce similar transcriptional programs. However, type III IFNs are unique in their cell specific receptor expression and their antitumor activity is specific to a narrow range of cell types. Thus, type III IFN based therapies may show reduced toxic side effects compared with type I IFN based treatment. In this review, we focus on the development of IFN-based therapeutics used to treat different tumors. We highlight how the development in cytokine engineering has allowed for efficient delivery of type I and type III IFNs to tumor sites and look ahead to the obstacles that are still associated with IFN-based therapies before they can be fully and safely integrated into clinical settings.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Interferons alone have continued to be explored as therapies. Recent advances in protein engineering and nanomedicine have shown novel methods to enhance the pharmacokinetics of interferons when administered as immunotherapeutic drugs. This review discusses how type I and type III interferons have been engineered to enhance their pharmacodynamic properties for safer delivery. We also discuss how these methods have been explored in tumor models and patient clinical trials.
Interferons alone have continued to be explored as therapies. Recent advances in protein engineering and nanomedicine have shown novel methods to enhance the pharmacokinetics of interferons when administered as immunotherapeutic drugs. This review discusses how type I and type III interferons have been engineered to enhance their pharmacodynamic properties for safer delivery. We also discuss how these methods have been explored in tumor models and patient clinical trials. Le texte complet de cet article est disponible en PDF.
Highlights |
• | Innovations in cytokine engineering have improved interferon-based therapies. |
• | Type I IFNs are engineered to use as cytokine-based therapies against tumors. |
• | Type III IFNs demonstrate therapeutic potential for cancer treatment. |
Keywords : Type I interferons, Type III interferons, Cytokine engineering, Interferon-based therapies, Immunotherapy, Tumor microenvironment
Plan
Vol 179
Article 117426- octobre 2024 Retour au numéro
Article précédent
- New insight into oxidative stress and inflammatory responses to kidney stones: Potential therapeutic strategies with natural active ingredients
- Yue Sun, Hongmei Sun, Zhengze Zhang, Futing Tan, Yunxia Qu, Xiaojing Lei, Qingzhu Xu, Jiangtao Wang, Lindan Shu, Huai Xiao, Zhibin Yang, Heng Liu
- Oral nano-formulations for endocrine therapy of endometrioid adenocarcinomas
- Minghua Cui, Yuehui Liu, Yangyang Liu, Tao Li, Xin Chen, Liu Da
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?